These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical grade iPS cells: need for versatile small molecules and optimal cell sources. Wu YL; Pandian GN; Ding YP; Zhang W; Tanaka Y; Sugiyama H Chem Biol; 2013 Nov; 20(11):1311-22. PubMed ID: 24267275 [TBL] [Abstract][Full Text] [Related]
5. Induced pluripotent stem cells and their potential for basic and clinical sciences. Ye L; Swingen C; Zhang J Curr Cardiol Rev; 2013 Feb; 9(1):63-72. PubMed ID: 22935022 [TBL] [Abstract][Full Text] [Related]
6. Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications. Liu G; David BT; Trawczynski M; Fessler RG Stem Cell Rev Rep; 2020 Feb; 16(1):3-32. PubMed ID: 31760627 [TBL] [Abstract][Full Text] [Related]
7. Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. Liu H; Ye Z; Kim Y; Sharkis S; Jang YY Hepatology; 2010 May; 51(5):1810-9. PubMed ID: 20432258 [TBL] [Abstract][Full Text] [Related]
8. Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells. Nakamura M; Okano H Cell Res; 2013 Jan; 23(1):70-80. PubMed ID: 23229514 [TBL] [Abstract][Full Text] [Related]
9. [Current status and perspective on regenerative medicine for spinal cord injury using iPS cell]. Nakamura M; Toyama Y; Okano H Rinsho Shinkeigaku; 2013; 53(11):1013-5. PubMed ID: 24291863 [TBL] [Abstract][Full Text] [Related]
11. A facile method to establish human induced pluripotent stem cells from adult blood cells under feeder-free and xeno-free culture conditions: a clinically compliant approach. Chou BK; Gu H; Gao Y; Dowey SN; Wang Y; Shi J; Li Y; Ye Z; Cheng T; Cheng L Stem Cells Transl Med; 2015 Apr; 4(4):320-32. PubMed ID: 25742692 [TBL] [Abstract][Full Text] [Related]
12. Translational prospects for human induced pluripotent stem cells. Csete M Regen Med; 2010 Jul; 5(4):509-19. PubMed ID: 20632855 [TBL] [Abstract][Full Text] [Related]
14. Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery. Gunaseeli I; Doss MX; Antzelevitch C; Hescheler J; Sachinidis A Curr Med Chem; 2010; 17(8):759-66. PubMed ID: 20088756 [TBL] [Abstract][Full Text] [Related]
15. Potentialities of induced pluripotent stem (iPS) cells for treatment of diseases. Chakraborty C; Shah KD; Cao WG; Hsu CH; Wen ZH; Lin CS Curr Mol Med; 2010 Nov; 10(8):756-62. PubMed ID: 20937020 [TBL] [Abstract][Full Text] [Related]
16. An introduction to induced pluripotent stem cells. Hanley J; Rastegarlari G; Nathwani AC Br J Haematol; 2010 Oct; 151(1):16-24. PubMed ID: 20666774 [TBL] [Abstract][Full Text] [Related]
17. Retention of Somatic Memory Associated with Cell Identity, Age and Metabolism in Induced Pluripotent Stem (iPS) Cells Reprogramming. Khoo TS; Jamal R; Abdul Ghani NA; Alauddin H; Hussin NH; Abdul Murad NA Stem Cell Rev Rep; 2020 Apr; 16(2):251-261. PubMed ID: 32016780 [TBL] [Abstract][Full Text] [Related]
18. The efficient generation of induced pluripotent stem (iPS) cells from adult mouse adipose tissue-derived and neural stem cells. Tat PA; Sumer H; Jones KL; Upton K; Verma PJ Cell Transplant; 2010; 19(5):525-36. PubMed ID: 20144262 [TBL] [Abstract][Full Text] [Related]
19. Induced pluripotent stem cells: a new approach for physiological research. Pfannkuche K; Hannes T; Khalil M; Noghabi MS; Morshedi A; Hescheler J; Dröge P Cell Physiol Biochem; 2010; 26(2):105-24. PubMed ID: 20798495 [TBL] [Abstract][Full Text] [Related]
20. Effects of reprogramming on genomic imprinting and the application of pluripotent stem cells. Li X; Li MJ; Yang Y; Bai Y Stem Cell Res; 2019 Dec; 41():101655. PubMed ID: 31734645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]